Patent application number | Description | Published |
20080280820 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 11-13-2008 |
20080306008 | Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 12-11-2008 |
20090062192 | Dimeric Peptide Agonists of the Glp-1 Receptor - Dimerization of GLP-1 agonists and therapeutic uses thereof. | 03-05-2009 |
20090203581 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 08-13-2009 |
20090318353 | Acylated Exendin-4 Compounds - This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such. | 12-24-2009 |
20100022454 | Peptides with High Affinity for the Prolactin Receptor - The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73. | 01-28-2010 |
20100022456 | Dimeric Prolactin Receptor Ligands - The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer. | 01-28-2010 |
20100035814 | N-Terminal Pegylated Prolactin Receptor Molecules - The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants. | 02-11-2010 |
20100249029 | Peptides with high affinity for the prolactin receptor - The invention relates to variants of prolactin, which variants have high affinity for the prolactin receptor. | 09-30-2010 |
20100292444 | Novel Prolactin Compounds - The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation. | 11-18-2010 |
20120283170 | Acylated Exendin-4 Compounds - This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such. | 11-08-2012 |